Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current

• US 8,753,674 B2
• Filed: 06/03/2012
• Issued: 06/17/2014
• Est. Priority Date: 06/03/2011
• Status: Active Grant

• Current Assignee: SignPath Pharma, Inc.
• Original Assignee: SignPath Pharma, Inc.
• Inventors: Helson, Lawrence
• Primary Examiner(s): Krass, Frederick
• Assistant Examiner(s): Roney, Celeste A
• Application Number:
  US13/487,233
• Publication Number:
  US 20120308643A1
• Time in Patent Office: 744 Days
• Field of Search: None
• US Class Current: 424/450
• CPC Class Codes: A61K 31/12 Ketones
• CPC Class Codes: A61K 31/445 Non condensed piperidines, e.g. piperocaine
• CPC Class Codes: A61K 31/4545 containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: Y10S 977/773 Nanoparticle, i.e. structure having three dimensions of 100 nm or less
• CPC Class Codes: Y10S 977/906 Drug delivery
• CPC Class Codes: Y10S 977/907 Liposome

Abstract

Compositions and methods for the treatment of drug-induced long QT syndrome and other cardiac channelopathies are disclosed herein. The compositions and methods of the present invention comprise binding one or more QT prolonging drugs with a liposome prior to parenteral (intravenous or subcutaneous) administration, or administration of an empty liposome prior to or concomitantly with therapeutic agents known to have a high risk of QT prolongation, or immediately following an envenomation. The results presented show an abrogation of the adverse effects of QT prolonging drugs in a dose-dependent manner by the compositions of the present invention.

Claims

1. A method for preventing or treating one or more cardiac channelopathies, irregularities or alterations in cardiac patterns induced by the administration of one or more drugs in a human or animal subject comprising the steps of:

identifying the human or animal subject in need of prevention or treatment of the one or more cardiac channelopathies, irregularities or alterations in cardiac patterns induced by the administration of one or more drugs; and

administering to the human or animal subject a therapeutically effective amount of a composition to prevent or treat one or more cardiac channelopathies, irregularities or alterations in cardiac patterns caused by the administered composition wherein the composition comprises at least one or more drugs capable of inducing one or more cardiac channelopathies, irregularities or alterations in cardiac patterns, the composition comprising;

one or more pharmacologically active agents selected from one or more drug classes comprising β

-blockers, sodium channel blockers, potassium supplements, potassium channel openers, hERG current enhancers, calcium channel blockers, agents for correcting trafficking defects, gap junction coupling enhancers, or any combinations thereof;

one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the pharmacologically active agent; and

an optional pharmaceutically acceptable dispersion medium, solvent, or vehicle, wherein the active agent, the liposome or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle.

2. The method of claim 1, wherein the cardiac channelopathy or the irregularity or alteration in the cardiac pattern is selected from the group consisting of long QT syndrome (LQTS), atrial flutter, atrial fibrillation, ventricular tachycardia, sinus bradycardia, sinus tachycardia, atrial tachycardia, atrial fibrillation, atrial flutter, atrioventricular nodal block, atrioventricular node reentry tachycardia, atrioventricular reciprocating tachycardia, ventricular tachycardia, ventricular fibrillation, or any combinations thereof.

3. The method of claim 1, wherein the cardiac condition is LQTS.

4. The method of claim 3, wherein the LQTS is a genetic condition.

5. The method of claim 1, wherein the composition treats LQTS induced by administration of one or more drugs.

6. The method of claim 1, wherein the one or more drugs comprise Aloxi or palonasitron HCL, Amiodarone, Arsenic trioxide, Astemizole, Bepridil, Chloroquine-Chlorpheniramine, Chlorpromazine, Cisapride, Celaxa, Clarithromycin, Erythromycin, Curcumin, Disopyramide, Dofetilide, Domperidone, Doxorubicin, Dronedarone, Droperidol, Grepafloxacin, Haldol, Haloperidol, Halofantrine, Ibutilide, Levomethadyl, Lidoflazine, Loratidine, Lovostatin, Mesoridazone, Methadone, Methanesulphonanilide, Moxifloxacin, Pentamadine, Pimozide, Prenylamine, Probucol, Procainamide, Propafenone, Pyrilamine, Quinidine-Terfenidine, Sertindole, Sotalol, Sparfloxacin, and Thioridazine.

7. A method for preventing or treating long QT syndrome (LQTS) arising from administration of a therapeutically active agent or a drug in a human or animal subject comprising the steps of:

identifying the human or animal subject in need of prevention or treatment of the long QT syndrome (LQTS) arising from the administration of the therapeutically active agent or the drug; and

administering to the human or animal subject a therapeutically effective amount of a composition comprising;

one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the therapeutically active agent or the drug; and

an optional pharmaceutically acceptable dispersion medium, solvent, or vehicle, wherein the active agent, the liposome or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle.

8. A method for preventing or treating long QT syndrome (LQTS) arising from administration of Terfenidine or Methanesulphonanilide for treatment of a cardiac condition or a disease in a human or animal subject comprising the steps of:

identifying the human or animal subject in need of prevention or treatment of the LQTS arising from the administration of Terfenidine or Methanesulphonanilide; and

administering to the human or animal subject a therapeutically effective amount of a composition comprising;

one or more liposomes, wherein the liposomes are empty liposomes and administered prior to, concomitantly, or after administration of the Terfenidine or Methanesulphonanilide; and

an optional pharmaceutically acceptable dispersion medium, solvent, or vehicle, wherein the Terfenidine or Methanesulphonanilide the liposome or both are dissolved, dispersed, or suspended in the medium, the solvent, or the vehicle.